About the Book
Due to the lack of secure, efficient, and patient-friendly therapies for neurodegenerative disorders, there is a rising demand for innovative approaches. Despite the limited number of nanocarriers approved for human use, they have demonstrated significant potential in preclinical and, in some instances, clinical trials. In alignment with this objective, the chapters of the book are structured to offer a comprehensive overview of recent advancements in medication and dosage form development, specifically emphasizing the nanoparticulate system for targeting the brain. This book aims to furnish readers with a thorough understanding of the clinical application of nanocarrier systems for treating neurodegenerative disorders, encompassing the latest developments, challenges, safety concerns, toxicity issues, regulatory considerations, prospects, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain will find valuable insights in this resource.
Key Features
Provides a comparative perspective of various nanocarrier systems, therefore facilitating the researcher's selection of appropriate nanoparticulate carriers
Highlights the related restrictions of brain delivery and current available medicines
Includes information on the advantages and disadvantages of various biomaterials utilized in the development of nanocarriers for brain targeting
Emphasizes distinct facets of surface functionalization according to the brain area of interest
Presents the current advances, preclinical and clinical development, and the future potential of multiple brain-targeting technologies
Table of Contents:
SECTION-I: NANOMEDICINE IN NEURODEGENERATIVE DISORDERS
Ch1 - Fundamentals of Brain–Barrier Anatomy and Global Functions
Yasser Mecheri, Soundous Malak Behloul
Ch2 - Blood Brain Barrier in Neurodegenrative Disorders
Adejoke Elizabeth Memudu, Michael Oluwatosin Gabriel
Ch3 - Neurodegenerative Disorders, available therapies, and their limitations
Mohamed Zaki , Eman E. Mohamed , Osama M. Ahmed
Ch4 - Challenges in brain targeting and mechanism of drug transfer across BBB
Ahmad Kodous, Priya Ramanathan, Arunagiri Kuha Deva Magendhra Rao, Gamal Abdel Nasser Atia
Ch5 - Introduction to Nanomedicine, Nanotechnology and Nanopharmaceuticals
Abdullah M. M. Elbadry, Hend H. Mohamed
Ch6 - Regulations and Ethics of Nanomedicine and Public acceptance
Nada Abdel-Monaem
Ch7 - Safety of Nanoparticles in Medicine
Mona Mohammed Abd elHakeem khalifa
Ch8 - Enhancing Brain Drug Delivery with Lipid Nanocarriers for Bioactive Compounds
Shivakumar M Methri, Sivakumar Manickam, V. Ravichandiran, Subramanian Natesan
Ch9 - Blood brain Barrier disruption and Nanomedicine in Neurodegenerative disorders
Adejoke Elizabeth Memudu, Michael Oluwatosin Gabriel, Grace Temitope Akingbade, Happiness Ochi Inyang, Omamuyovwi Meashack Ijomone
Ch10 - Worldwide Development and Commercialization of Nanomedicine
Hadeer N. Atalah, Esraa M. Qansuwa
SECTION-II: NANOPARTICLES AND NEURODEGENERATIVE DISORDERS
Ch11 - Introduction to nanoparticles as a potential carrier for brain targeting in Neurodegenerative Disorders
Adejoke Elizabeth Memudu, Michael Oluwatosin Gabriel, Victor Ebube Anadu, Olayemi Kafilat Ijomone, Omamuyovwi Meashack Ijomone
Ch12 - Application of polymeric nanoparticles in brain targeting
Moshera Samy
Ch13 - Lipid-based Nanocarriers for Brain Delivery of Bio-actives in the Treatment of Neurodegenerative Disorders
Khaled M. Kotb, Mohamed N. Sharafeldin, Hamsa Hassan, Achouak BOUTALBI, Ahmed Yahya, Haseen Fatima Niazi, Nouran A. Taha, Islam Omar, Amgad E. Salem
Ch14 - Autophagy and extracellular nanovesicles communication and their therapeutic application in neurodegenerative diseases.
Mohamed Abdelkader, Noha AboQuella
Ch15 - Mesoporous silica nanoparticles as promising carriers for brain delivery
Sudarshan Naidu Chilamakuri, Sivakumar Manickam, Rajukumar Malayandi Ravichandiran Velayutham, Subramanian Natesan
Ch16 - Potential of dendrimers as a nanocarrier for brain drug delivery
Arab Iram Saba Gaus Mohammed, Victor Hmingthansanga, Sivakumar Manickam, V. Ravichandiran, Subramanian Natesan
Ch17 - Surface active ligands for brain targeting
Mariam Zewail, Heba Abd-El-Azim
Ch18 - Nanocarriers for brain delivery: Safety, Stability concerns, and regulatory aspects
Asmaa Ashraf, Mohamed Dahab, Rahma Soliman
Ch19 - Advancements of nanocarriers for brain targeting and limitations in clinical translation
Nermeen Z. Abuelezz, Fayza Eid Nasr, María-Salud García-Ayllón, Javier Sáez-Valero
Ch20 - Toward Applicability of Exosomal-ncRNA Precision vs Nanoparticles to the Brain
Nadia M. Hamdy, Emad B. Basalious, Mona G. El-Sisi, Rana A. Youness, Ahmed S. Sultan
Ch21 - Current advancements of nanocarriers for neurodegenerative disorders linked to toxoplasmosis
Mohamed Y. Zaky, Nahed S. Lamloum
Ch22 - Toward Nano-drugs Precision for Neurodegenerative disease(s) or Glioma
Nadia M. Hamdy, Emad B. Basalious, Al-Aliaa Sallam, Fatma H. Shaker, Sujay Paul, Shih-Min Hsia, Mai M. Anwar
About the Author :
Dr. Wael Mohamed Yousef Mohamed, a Physician Neuroscientist, earned his PhD from PSU in the USA and currently holds the position of Associate Professor at IIUM Medical School in Malaysia. With an extensive background, Dr. Mohamed has been invited to deliver over 150 lectures both domestically and internationally. His contributions to Neuroscience/Psychiatry are notable, with the publication of more than 100 peer-reviewed papers, boasting an h-index of 20. Furthermore, Dr. Mohamed serves as an editor for Frontiers in Neurology and PLOS-ONE Journals, where he has contributed to various journal special issues on brain disorders. In the realm of book editing, he is actively involved with Springer, CRC, and Cambridge in the field of neuroscience. His research endeavors have attracted numerous grants from esteemed national and international organizations, including IBRO, ISN, MJF, STDF, FRGS, and INDO-ASEAN, amounting to a total research funding of half a million US$. Notably, he is the founder and chair of the AfrAbia-PD-Genomic Consortium.
